Trybe Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Trybe Capital Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-94,519	Closed	-$7.03M	–	15
2023 Q2	$7.03M	Buy	94,519 +68,160	+259%	+$4.03M	2.43%	15
2023 Q1	$1.4M	Buy	+26,359	New	+$1.67M	0.77%	12
2022 Q4	–	Sell	-26,359	Closed	-$3.29M	–	11
2022 Q3	$3.29M	Hold	26,359	–	–	2.23%	12
2022 Q2	$2.51M	Sell	26,359 -3,841	-13%	-$468K	2.06%	11
2022 Q1	$4.87M	Hold	30,200	–	–	2.03%	11
2021 Q4	$10M	Hold	30,200	–	–	4.11%	11
2021 Q3	$14M	Buy	+30,200	New	+$14.7M	7.97%	7

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Trybe Capital Management's DNA Position: Q3 2023 in Review

Trybe Capital Management sold out of Ginkgo Bioworks (DNA) in Q3 2023, closing a stake of 94,519 shares — an estimated $7.03M sold.

Trybe Capital Management first reported a position in DNA in Q3 2021 and held it in 7 quarters. The position peaked at $14M in Q3 2021. 348 funds tracked by Wall St. Rank hold DNA as of Q3 2023.

Trybe Capital Management reported no remaining Ginkgo Bioworks position as of Q3 2023 after selling out during the quarter.
Trybe Capital Management sold 94,519 Ginkgo Bioworks shares in Q3 2023, an estimated $7.03M.
Trybe Capital Management first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 7 quarters.
Trybe Capital Management's Ginkgo Bioworks position peaked at $14M in Q3 2021.
348 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2023.

Based on Trybe Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.